Evoke Pharma (EVOK) – Press Releases
-
Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications
-
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer
-
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
-
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024
-
Evoke Pharma Announces Closing of $7.5 Million Public Offering
-
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
-
Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent
-
United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI
-
Evoke Pharma Reports Third Quarter 2023 Financial Results
-
Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of
-
Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College
-
Evoke Pharma’s Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presen
-
Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®
-
Evoke Pharma Reports Second Quarter 2023 Financial Results
-
Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting
-
Evoke Pharma and EVERSANA Announce Abstract Selection for Plenary Oral Presentation at The American College of Gastroenterology (ACG) 2023 Annual Meeting
-
Evoke Pharma to Host First Key Opinion Leader Webinar on Healthcare Resource Utilization Data Related to Gastroparesis and its Treatment
-
Evoke Pharma Reports First Quarter 2023 Financial Results
-
Real-World Data Presented by Evoke Pharma and EVERSANA at Digestive Disease Week 2023 Shows Gimoti® Meaningfully Reduces Utilization of Healthcare Resources
-
Evoke Pharma’s Real-World Healthcare Utilization Data Comparing GIMOTI® to Oral Metoclopramide to Be Presented at Digestive Disease Week (DDW) 2023
-
New GIMOTI Patent Listed in FDA Orange Book
-
United States Patent and Trademark Office (USPTO) Grants Evoke Pharma a Formulation Patent Covering GIMOTI
-
Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI-Related Patent
-
Evoke Pharma & EVERSANA Announce Compelling Real-World Data on the Impact of GIMOTI in Reducing the Utilization of Healthcare Resources to be Presented at the Academy of Managed Care Pharmacy (AMC
-
Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial Results
-
Evoke Pharma to Report Fourth Quarter and Full Year 2022 Results on March 21, 2023
-
Evoke Pharma and EVERSANA Selected to Present Results of Real-World Healthcare Utilization Study Comparing GIMOTI® and Oral Metoclopramide at the Digestive Disease Week Plenary Session
-
Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti
-
Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023
-
USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI® To Treat Moderate to Severe Gastroparesis
-
Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI®
-
Evoke Pharma Reports Record Third Quarter 2022 Financial Results
-
Evoke Pharma to Report Third Quarter Results on November 9, 2022
-
Evoke Pharma to Participate in the 2022 American College of Gastroenterology Annual Scientific Meeting
-
Evoke Pharma Receives Notice of Allowance from USPTO for a Patent Related to GIMOTI
-
GIMOTI Receives Nomination for 2022 Healio Industry Breakthrough Award
-
Evoke Pharma to Participate in H.C. Wainwright 24th Annual Global Investment Conference
-
Evoke Pharma and EVERSANA Expand Patient Access to GIMOTI® With New Telehealth Solution
-
Evoke Pharma Reports Second Quarter 2022 Financial Results
-
Evoke Pharma to Report Second Quarter Results on August 10, 2022
-
Evoke Pharma Recognizes Gastroparesis Awareness Month through its Support of The International Foundation for Gastrointestinal Disorders (IFFGD)
-
Evoke Pharma Expands IP Portfolio with Addition of Canadian Patent Covering GIMOTI Method of Use
-
Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program
-
Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update
-
Real-World Data Analysis Reveals a Lower Risk of Tardive Dyskinesia (TD) with Metoclopramide than Previously Reported
-
Patient Experience Survey Reported Positive Findings for GIMOTI®
-
Evoke Pharma to Present at H.C. Wainwright Global Investment Conference
-
Evoke Pharma Reports First Quarter 2022 Financial Results
-
Evoke Pharma to Report First Quarter 2022 Financial Results on May 10, 2022
-
Evoke Pharma Granted FDA Market Exclusivity for GIMOTI®
Back to EVOK Stock Lookup
